CN110075307A - 腹膜治疗液 - Google Patents

腹膜治疗液 Download PDF

Info

Publication number
CN110075307A
CN110075307A CN201910196687.3A CN201910196687A CN110075307A CN 110075307 A CN110075307 A CN 110075307A CN 201910196687 A CN201910196687 A CN 201910196687A CN 110075307 A CN110075307 A CN 110075307A
Authority
CN
China
Prior art keywords
peritoneal
acid
compound
treatment fluid
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910196687.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·格伦茨曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
O F Tai Lee Von Health Joint-Stock Co
Original Assignee
O F Tai Lee Von Health Joint-Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O F Tai Lee Von Health Joint-Stock Co filed Critical O F Tai Lee Von Health Joint-Stock Co
Publication of CN110075307A publication Critical patent/CN110075307A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
CN201910196687.3A 2015-07-20 2016-07-19 腹膜治疗液 Pending CN110075307A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
EP15177544.2 2015-07-20
CN201680042681.5A CN107921009B (zh) 2015-07-20 2016-07-19 腹膜治疗液

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680042681.5A Division CN107921009B (zh) 2015-07-20 2016-07-19 腹膜治疗液

Publications (1)

Publication Number Publication Date
CN110075307A true CN110075307A (zh) 2019-08-02

Family

ID=53785450

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910196687.3A Pending CN110075307A (zh) 2015-07-20 2016-07-19 腹膜治疗液
CN201680042681.5A Active CN107921009B (zh) 2015-07-20 2016-07-19 腹膜治疗液

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680042681.5A Active CN107921009B (zh) 2015-07-20 2016-07-19 腹膜治疗液

Country Status (23)

Country Link
US (2) US20180221303A1 (https=)
EP (2) EP3120842A1 (https=)
JP (1) JP6448847B2 (https=)
KR (2) KR102266889B1 (https=)
CN (2) CN110075307A (https=)
AU (1) AU2016296216B2 (https=)
BR (1) BR112018001005B1 (https=)
CA (1) CA2990532C (https=)
CO (1) CO2018000236A2 (https=)
CY (1) CY1124467T1 (https=)
DK (1) DK3324951T3 (https=)
ES (1) ES2880796T3 (https=)
HR (1) HRP20211319T1 (https=)
HU (1) HUE055208T2 (https=)
LT (1) LT3324951T (https=)
MX (1) MX387020B (https=)
PL (1) PL3324951T3 (https=)
PT (1) PT3324951T (https=)
RS (1) RS62142B1 (https=)
RU (1) RU2718908C2 (https=)
SI (1) SI3324951T1 (https=)
SM (1) SMT202100428T1 (https=)
WO (1) WO2017013120A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) * 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
CA3116556A1 (en) 2018-10-16 2020-04-23 President And Fellows Of Harvard College Sirt1 activating compounds
WO2025265015A1 (en) * 2024-06-20 2025-12-26 Barinta Therapeutics, Inc. Flavylium cations and electrolyte complexes thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1458850A (zh) * 2000-09-13 2003-11-26 科学技术振兴事业团 腹膜透析液及其制备方法
CN1725996A (zh) * 2002-12-10 2006-01-25 甘布罗伦迪亚股份有限公司 用于生产腹膜透析药物的医用溶液的制备方法
WO2011107630A1 (es) * 2010-03-05 2011-09-09 Universidad De Castilla La Mancha Solución para diálisis peritoneal
CN102264348A (zh) * 2008-11-26 2011-11-30 脂蛋白技术有限公司 生物活性提高的白藜芦醇制剂
WO2013098140A1 (en) * 2011-12-27 2013-07-04 Zytoprotec Gmbh Peritoneal dialysis fluid comprising a gsk-3 inhibitor
CN103330715A (zh) * 2013-07-01 2013-10-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
JP2003507345A (ja) * 1999-08-10 2003-02-25 エムエル ラボラトリーズ ピーエルシー デキストリン溶液を使用した治療薬剤の送達方法
AU7879500A (en) 1999-10-15 2001-04-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
AU2002341566A1 (en) * 2001-08-16 2003-04-01 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
AU2004290580A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic PEG solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20090162457A1 (en) 2005-10-26 2009-06-25 Kao Corporation Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
WO2009017866A1 (en) * 2007-07-31 2009-02-05 Elc Management Llc Cosmetic compositions containing resveratrol derivatives
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
EP3085365A3 (en) * 2009-01-19 2017-01-04 Lycored Ltd. Synergistic combinations of carotenoids and polyphenols
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
JP6240665B2 (ja) * 2012-04-24 2017-11-29 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ポリマー系透析物
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1458850A (zh) * 2000-09-13 2003-11-26 科学技术振兴事业团 腹膜透析液及其制备方法
CN1725996A (zh) * 2002-12-10 2006-01-25 甘布罗伦迪亚股份有限公司 用于生产腹膜透析药物的医用溶液的制备方法
CN102264348A (zh) * 2008-11-26 2011-11-30 脂蛋白技术有限公司 生物活性提高的白藜芦醇制剂
WO2011107630A1 (es) * 2010-03-05 2011-09-09 Universidad De Castilla La Mancha Solución para diálisis peritoneal
WO2013098140A1 (en) * 2011-12-27 2013-07-04 Zytoprotec Gmbh Peritoneal dialysis fluid comprising a gsk-3 inhibitor
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol
CN103330715A (zh) * 2013-07-01 2013-10-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GOTLOIB LAZARO: "Mechanisms of Cell Death during Peritoneal Dialysis A Role for Osmotic and Oxidative Stress", 《PERITONEAL DIALYSIS – FROM BASIC CONCEPTS TO CLINICAL EXCELLENCE》 *
MUNEHIRO KITADA等: "Renal protective effects of resveratrol", 《OXIDATIVE MEDICINE AND CELLULAR LONGEVITY》 *
伍军等: "白藜芦醇对腹膜透析液作用下人腹膜间皮细胞线粒体活性氧产生的影响", 《医学研究杂志》 *
徐元贞: "《新全实用药物手册》", 28 February 2005, 河南科学技术出版社 *
陈香美: "《实用腹膜透析操作教程》", 31 May 2013, 人民军医出版社 *

Also Published As

Publication number Publication date
ES2880796T3 (es) 2021-11-25
DK3324951T3 (da) 2021-08-23
JP6448847B2 (ja) 2019-01-09
CY1124467T1 (el) 2022-07-22
EP3324951B1 (en) 2021-05-26
CO2018000236A2 (es) 2018-06-12
CA2990532C (en) 2020-07-14
BR112018001005A2 (pt) 2022-09-06
JP2018522894A (ja) 2018-08-16
HK1251176A1 (zh) 2019-01-25
RU2018106122A (ru) 2019-08-20
AU2016296216B2 (en) 2019-05-02
RU2718908C2 (ru) 2020-04-15
US20200022926A1 (en) 2020-01-23
CN107921009A (zh) 2018-04-17
MX2018000336A (es) 2018-05-22
KR20180048577A (ko) 2018-05-10
HUE055208T2 (hu) 2021-11-29
US11160766B2 (en) 2021-11-02
BR112018001005B1 (pt) 2023-11-28
MX387020B (es) 2025-03-19
SMT202100428T1 (it) 2021-09-14
AU2016296216A1 (en) 2017-12-14
CA2990532A1 (en) 2017-01-26
LT3324951T (lt) 2021-07-26
EP3324951A1 (en) 2018-05-30
HRP20211319T1 (hr) 2021-11-26
WO2017013120A1 (en) 2017-01-26
PT3324951T (pt) 2021-07-20
KR20190025759A (ko) 2019-03-11
EP3120842A1 (en) 2017-01-25
KR102266889B1 (ko) 2021-06-18
US20180221303A1 (en) 2018-08-09
PL3324951T3 (pl) 2021-12-13
RU2018106122A3 (https=) 2019-10-10
RS62142B1 (sr) 2021-08-31
SI3324951T1 (sl) 2021-09-30
CN107921009B (zh) 2020-12-11

Similar Documents

Publication Publication Date Title
US11160766B2 (en) Peritoneal therapeutic fluid
ES2370478T3 (es) Carbohidratos antiadhesivos.
HK40011489A (en) Peritoneal therapeutic fluid
JP5474353B2 (ja) ヒドロゲルを形成する熱可塑性の中性化されたキトサン組成物、凍結乾燥体、およびこれらを生成する方法
HK1251176B (zh) 腹膜治疗液
US11185514B2 (en) Aqueous solution comprising a polyphenol
ES2691872T3 (es) Aminofucoidan como un vector para la fibrinolisis en enfermedades trombóticas
CN116650425B (zh) 糖酯化合物或其盐在冷冻保护、冷冻干燥保护中的应用
RU2749443C2 (ru) Углеводные композиции для диализа
GB2345247A (en) Pyruvic acid formulations
HK1254524B (en) Aqueous solution comprising a stilbenoid

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011489

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190802

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40011489

Country of ref document: HK